Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02798861 · ClinicalTrials.gov registry record
Controlled Attenuation Parameter (CAP) in Liver Allografts
A clinical trial, sponsored by Andres Duarte-Rojo.
- Completed
- Registry status
- 160
- Enrollment target
NCT02798861 is a clinical trial that has completed, run by Andres Duarte-Rojo. The registered enrollment target is 160 participants.
The verdict
NCT02798861 has completed, sponsored by Andres Duarte-Rojo.
- COMPLETED
- Registry status
- 160 participants
- Enrollment target
Study Summary
The primary aim is to determine the accuracy of CAP in the quantification of liver steatosis using liver biopsies as reference. Secondarily, investigators will correlate transient elastography (TE) and CAP results, analyze possible associations between CAP/TE and post-liver transplant (LT) clinical outcomes, and evaluate the change in CAP after LT. The study aims to include as many donors as needed to achieve at least 120 transplanted liver allografts.
Interventions
- DEVICE Fibroscan 402/530
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2016-09-07 |
| Est. Completion | 2019-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02798861
The ClinicalTrials.gov registry entry for NCT02798861 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andres Duarte-Rojo, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fibroscan 402/530 is the first listed.
NCT02798861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02798861 about?
NCT02798861 is a clinical study titled "Controlled Attenuation Parameter (CAP) in Liver Allografts". The primary aim is to determine the accuracy of CAP in the quantification of liver steatosis using liver biopsies as reference. Secondarily, investigators will correlate transient elastography (TE) and CAP results, analyze possible associations between CAP/TE and post-liver transplant (LT) clinical ...
What is the current status of trial NCT02798861?
This trial is currently completed. The enrollment target is 160 participants. The study started on 2016-09-07. Estimated completion is 2019-06-01.
What interventions are being tested in trial NCT02798861?
The interventions under investigation include: Fibroscan 402/530 (DEVICE).
Who is sponsoring clinical trial NCT02798861?
This trial is sponsored by Andres Duarte-Rojo, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.